3B Blackbio Dx Limited (NSE:3BBLACKBIO)
India · Delayed Price · Currency is INR 1,253.40
+51.90 (4.32%)
At close: Jun 10, 2026
3B Blackbio Dx Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,419 | 964.69 | 741.25 | 618.36 | 806.46 |
Other Revenue | - | - | 2.89 | 2.32 | 69.03 |
| 1,419 | 964.69 | 744.13 | 620.68 | 875.5 | |
Revenue Growth (YoY) | 47.11% | 29.64% | 19.89% | -29.10% | -61.87% |
Cost of Revenue | 358.55 | 260.63 | 221.39 | 179.16 | 318.29 |
Gross Profit | 1,061 | 704.06 | 522.75 | 441.52 | 557.2 |
Selling, General & Admin | 239.65 | 79.32 | 71.02 | 50.27 | 38.34 |
Other Operating Expenses | 235.83 | 120.21 | 117.12 | 93.1 | 78.85 |
Operating Expenses | 526.73 | 210.4 | 198.71 | 152 | 123.91 |
Operating Income | 533.9 | 493.66 | 324.04 | 289.52 | 433.3 |
Interest Expense | -2.37 | -1.09 | -1.25 | -1.98 | -1.06 |
Interest & Investment Income | - | 84.19 | 61.66 | 38.71 | - |
Currency Exchange Gain (Loss) | - | 1.73 | 0.15 | 2.37 | - |
Other Non Operating Income (Expenses) | 255.58 | 0.64 | 0.75 | -3.35 | -0 |
EBT Excluding Unusual Items | 787.11 | 579.14 | 385.36 | 325.26 | 432.23 |
Merger & Restructuring Charges | -17.41 | - | - | - | - |
Gain (Loss) on Sale of Investments | - | 60.59 | 57.86 | 27.84 | - |
Gain (Loss) on Sale of Assets | - | 0.25 | 0.1 | - | - |
Pretax Income | 769.7 | 639.98 | 443.32 | 353.1 | 432.23 |
Income Tax Expense | 170.4 | 163.07 | 122.31 | 93.73 | 110.24 |
Earnings From Continuing Operations | 599.3 | 476.91 | 321.01 | 259.37 | 322 |
Minority Interest in Earnings | -13.44 | - | - | - | - |
Net Income | 585.86 | 476.91 | 321.01 | 259.37 | 322 |
Net Income to Common | 585.86 | 476.91 | 321.01 | 259.37 | 322 |
Net Income Growth | 22.84% | 48.57% | 23.77% | -19.45% | -71.72% |
Shares Outstanding (Basic) | 8 | 9 | 9 | 9 | 7 |
Shares Outstanding (Diluted) | 8 | 9 | 9 | 9 | 7 |
Shares Change (YoY) | -2.24% | - | 0.02% | 14.34% | 0.00% |
EPS (Basic) | 69.94 | 55.66 | 37.46 | 30.28 | 42.98 |
EPS (Diluted) | 69.94 | 55.66 | 37.46 | 30.28 | 42.98 |
EPS Growth | 25.66% | 48.57% | 23.74% | -29.55% | -71.72% |
Free Cash Flow | 269.66 | 424.53 | 264.43 | 182.6 | 350.63 |
Free Cash Flow Per Share | 32.19 | 49.55 | 30.86 | 21.32 | 46.80 |
Dividend Per Share | 5.000 | 4.000 | 3.000 | 2.500 | 2.500 |
Dividend Growth | 25.00% | 33.33% | 20.00% | - | 150.00% |
Gross Margin | 74.73% | 72.98% | 70.25% | 71.14% | 63.64% |
Operating Margin | 37.62% | 51.17% | 43.55% | 46.65% | 49.49% |
Profit Margin | 41.28% | 49.44% | 43.14% | 41.79% | 36.78% |
Free Cash Flow Margin | 19.00% | 44.01% | 35.53% | 29.42% | 40.05% |
EBITDA | 585.15 | 504.52 | 334.61 | 298.15 | 440.02 |
EBITDA Margin | 41.23% | 52.30% | 44.97% | 48.04% | 50.26% |
D&A For EBITDA | 51.26 | 10.86 | 10.57 | 8.63 | 6.72 |
EBIT | 533.9 | 493.66 | 324.04 | 289.52 | 433.3 |
EBIT Margin | 37.62% | 51.17% | 43.55% | 46.65% | 49.49% |
Effective Tax Rate | 22.14% | 25.48% | 27.59% | 26.54% | 25.50% |
Revenue as Reported | 1,675 | 1,116 | 866.57 | 690.62 | 875.5 |